KR20240155354A - 노보비오신 유사체 및 프롤린의 공-결정 형태 - Google Patents

노보비오신 유사체 및 프롤린의 공-결정 형태 Download PDF

Info

Publication number
KR20240155354A
KR20240155354A KR1020247033920A KR20247033920A KR20240155354A KR 20240155354 A KR20240155354 A KR 20240155354A KR 1020247033920 A KR1020247033920 A KR 1020247033920A KR 20247033920 A KR20247033920 A KR 20247033920A KR 20240155354 A KR20240155354 A KR 20240155354A
Authority
KR
South Korea
Prior art keywords
proline
crystal
crystals
xrpd
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247033920A
Other languages
English (en)
Korean (ko)
Inventor
신 장
존 알렌 월링
멜라니 제이. 베빌
크리스토퍼 에스. 시딕
자레드 피. 스미트
Original Assignee
리아타 파마슈티컬즈, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리아타 파마슈티컬즈, 아이엔씨. filed Critical 리아타 파마슈티컬즈, 아이엔씨.
Publication of KR20240155354A publication Critical patent/KR20240155354A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247033920A 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태 Ceased KR20240155354A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
US62/627,570 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline
KR1020207025571A KR102718111B1 (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025571A Division KR102718111B1 (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태

Publications (1)

Publication Number Publication Date
KR20240155354A true KR20240155354A (ko) 2024-10-28

Family

ID=65444361

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247033920A Ceased KR20240155354A (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태
KR1020207025571A Active KR102718111B1 (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207025571A Active KR102718111B1 (ko) 2018-02-07 2019-02-01 노보비오신 유사체 및 프롤린의 공-결정 형태

Country Status (19)

Country Link
US (3) US10717755B2 (https=)
EP (1) EP3749675B1 (https=)
JP (3) JP2021512910A (https=)
KR (2) KR20240155354A (https=)
CN (2) CN112020506B (https=)
AR (1) AR114245A1 (https=)
AU (3) AU2019217821B2 (https=)
BR (1) BR112020016205A2 (https=)
CA (2) CA3226385A1 (https=)
CL (2) CL2020002051A1 (https=)
CO (1) CO2020009761A2 (https=)
EA (1) EA202091885A1 (https=)
IL (2) IL276583B2 (https=)
MX (2) MX2020008326A (https=)
MY (1) MY209803A (https=)
PE (1) PE20211446A1 (https=)
SG (1) SG11202007530XA (https=)
TW (2) TWI797249B (https=)
WO (1) WO2019156907A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029369B2 (en) * 2010-09-23 2015-05-12 Nuformix Limited Aprepitant L-proline composition and cocrystal
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CA2892832C (en) * 2011-11-25 2020-04-14 Nuformix Technologies Limited Aprepitant l-proline solvates - compositions and cocrystals
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
SMT201900660T1 (it) * 2012-02-09 2020-01-14 Univ Kansas Inibitori c-terminali di hsp90
EP2890704B1 (en) * 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
MX388516B (es) * 2014-06-24 2025-03-20 Univ Kansas Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70.
KR20170060035A (ko) * 2014-09-30 2017-05-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE

Also Published As

Publication number Publication date
TWI868593B (zh) 2025-01-01
IL276583A (en) 2020-09-30
JP2026012851A (ja) 2026-01-27
US11401294B2 (en) 2022-08-02
EA202091885A1 (ru) 2021-01-15
TWI797249B (zh) 2023-04-01
AU2022283638B2 (en) 2024-07-25
CA3226385A1 (en) 2019-08-15
CN112020506A (zh) 2020-12-01
IL315865A (en) 2024-11-01
US20190241599A1 (en) 2019-08-08
MY209803A (en) 2025-08-05
MX2022012856A (es) 2022-11-30
SG11202007530XA (en) 2020-09-29
CN112020506B (zh) 2024-10-11
AU2022283638A1 (en) 2023-02-02
PE20211446A1 (es) 2021-08-05
MX2020008326A (es) 2020-09-28
CL2022003784A1 (es) 2023-06-09
CL2020002051A1 (es) 2021-02-19
NZ767558A (en) 2024-11-29
AR114245A1 (es) 2020-08-12
IL276583B1 (en) 2024-11-01
JP2021512910A (ja) 2021-05-20
EP3749675B1 (en) 2025-12-31
US20240043465A1 (en) 2024-02-08
KR102718111B1 (ko) 2024-10-17
US10717755B2 (en) 2020-07-21
WO2019156907A1 (en) 2019-08-15
BR112020016205A2 (pt) 2020-12-15
CA3090646C (en) 2024-02-27
TW201945381A (zh) 2019-12-01
JP2024001167A (ja) 2024-01-09
AU2019217821B2 (en) 2022-09-08
AU2024227646A1 (en) 2024-11-14
CO2020009761A2 (es) 2020-10-30
CN118894894A (zh) 2024-11-05
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
AU2019217821A1 (en) 2020-09-24
EP3749675A1 (en) 2020-12-16
CA3090646A1 (en) 2019-08-15
US20200347088A1 (en) 2020-11-05
IL276583B2 (en) 2025-03-01
TW202510893A (zh) 2025-03-16

Similar Documents

Publication Publication Date Title
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
JP5951506B2 (ja) プリン誘導体の結晶性形態
US20250002474A1 (en) Crystal of pyrrolidine compound
US20240043465A1 (en) Co-crystal forms of a novobiocin analog and proline
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
US20260022115A1 (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperdine compound
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
EA049105B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
TWI915111B (zh) 新生黴素（ｎｏｖｏｂｉｏｃｉｎ）類似物及脯胺酸之共晶型
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
TW200302830A (en) Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241011

Application number text: 1020207025571

Filing date: 20200904

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241028

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241128

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250310

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D